精彩内容近日,山东新华制药联合南京集萃剂鼎医药提交了瑞舒伐他汀依折麦布片(I)的4类仿制上市申请。瑞舒伐他汀依折麦布片(I)是血脂调节复方制剂潜力产品,赛诺菲的原研产品2025年Q1在中国三大终端六大市场飙涨29239%。目前,新华制药暂无血脂调节复方制剂获批,公司有望开拓新市场。图1:新华制药最新申报的产品来源:CDE官网瑞舒伐他汀依折麦布片(I)是由瑞舒伐他汀(HMG-CoA还原酶抑制剂)和...
Source Link精彩内容近日,山东新华制药联合南京集萃剂鼎医药提交了瑞舒伐他汀依折麦布片(I)的4类仿制上市申请。瑞舒伐他汀依折麦布片(I)是血脂调节复方制剂潜力产品,赛诺菲的原研产品2025年Q1在中国三大终端六大市场飙涨29239%。目前,新华制药暂无血脂调节复方制剂获批,公司有望开拓新市场。图1:新华制药最新申报的产品来源:CDE官网瑞舒伐他汀依折麦布片(I)是由瑞舒伐他汀(HMG-CoA还原酶抑制剂)和...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.